Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Rachel Thijssen; Andrew W. Roberts

doi:10.1016/j.ccell.2019.09.008

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Rachel Thijssen
, Andrew W. Roberts^*

^*Corresponding author for this work

Walter and Eliza Hall Institute of Medical Research
Peter Maccallum Cancer Centre
University of Melbourne
Victorian Comprehensive Cancer Centre

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

Original language	English
Pages (from-to)	341-343
Number of pages	3
Journal	Cancer cell
Volume	36
Issue number	4
DOIs	https://doi.org/10.1016/j.ccell.2019.09.008
Publication status	Published - 14 Oct 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ccell.2019.09.008

Cite this

@article{995e096fd5404cbaa479b4af8c5e4201,

title = "Venetoclax in Lymphoid Malignancies: New Insights, More to Learn",

abstract = "In this issue of Cancer Cell, Gui{\`e}za et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.",

author = "Rachel Thijssen and Roberts, \{Andrew W.\}",

note = "Funding Information: R.T. is supported by a Fellowship for the Leukemia and Lymphoma Society (5467-18), and A.W.R is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia ( 1079560 ). Funding Information: R.T. and A.W.R. are employees of the Walter and Eliza Hall Institute (WEHI), which receives milestone and royalty payments related to venetoclax. A.W.R. receives payments from WEHI related to venetoclax and has previously received research funding from AbbVie and Janssen. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = oct,

day = "14",

doi = "10.1016/j.ccell.2019.09.008",

language = "English",

volume = "36",

pages = "341--343",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Venetoclax in Lymphoid Malignancies

T2 - New Insights, More to Learn

AU - Thijssen, Rachel

AU - Roberts, Andrew W.

N1 - Funding Information: R.T. is supported by a Fellowship for the Leukemia and Lymphoma Society (5467-18), and A.W.R is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia ( 1079560 ). Funding Information: R.T. and A.W.R. are employees of the Walter and Eliza Hall Institute (WEHI), which receives milestone and royalty payments related to venetoclax. A.W.R. receives payments from WEHI related to venetoclax and has previously received research funding from AbbVie and Janssen. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/10/14

Y1 - 2019/10/14

N2 - In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

AB - In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

UR - https://www.scopus.com/pages/publications/85072930948

U2 - 10.1016/j.ccell.2019.09.008

DO - 10.1016/j.ccell.2019.09.008

M3 - Article

C2 - 31614111

SN - 1535-6108

VL - 36

SP - 341

EP - 343

JO - Cancer cell

JF - Cancer cell

IS - 4

ER -

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this